Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from LLY

Why Eli Lilly Shares Are Trading Higher Today

The FDA approved Eli Lilly And Co's (NYSE:LLY) injected drug tirzepatide, which has the brand name Mounjaro (tirzepatide), to help improve blood sugar control in adults with type 2 diabetes. The approval covers tirzepatide as an adjunct to diet and exercise. As the first and only FDA-approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1…

Benzinga

Eli Lilly's Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19

The FDA approved Eli Lilly And Co's (NYSE:LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval. The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat…

Benzinga

Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 21.54%. Currently, Eli Lilly has a market capitalization of $276.68 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Whale Trades For April 28

Benzinga's options scanner just detected over 16 options trades for Eli Lilly (NYSE:LLY) summing a total amount of $701,114. At the same time, our algo caught 4 for a total amount of 146,845.

Benzinga

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…

Benzinga

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion. Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. …

Benzinga

Think the Market is In for a Rough Ride? Then Add These 5 Stocks to Your Portfolio

The stock market seems set for a rough ride amid concerns about the Russia-Ukraine war, high inflation, and the Fed’s tightening monetary policy. Moreover, global growth is expected to slow due to the crisis in Europe and resurgent COVID-19 cases in China and elsewhere. Therefore, we think fundamentally strong stocks…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

5 Surging Mega-Cap Stocks to Add to Your Watchlist

The stock market has been experiencing high volatility due to various economic and geopolitical factors. But under these uncertain market conditions investors could add quality mega-cap stocks Novo Nordisk (NVO), Shell (SHEL), Eli Lilly (LLY), Novartis (NVS), and Costco (COST) to their watchlists. Mega-cap stocks are known to endure harsh…

StockNews.com

5 Global Healthcare Stocks to Buy as BofA Warns of a "Recession Shock"

The healthcare industry is well-positioned to ride out a potential recessionary shock, thanks in-part to the inelastic demand for COVID-19 vaccines worldwide. Thus, we think investors could invest in fundamentally sound healthcare stocks Pfizer Inc. (PFE), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Eli Lilly and Company (LLY), and Merck…

StockNews.com

Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis

Eli Lilly And Co (NYSE: LLY)

Benzinga

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

The healthcare sector is known for its defensive qualities. Therefore, betting on mega-cap healthcare stocks could be one of the best ways to generate stable returns amid the current, extended, market volatility. We think their solid growth attributes and profit margins make the stocks of Novartis (NVS), Danaher (DHR), Eli…

StockNews.com

Lilly Presents Updated Data On Retevmo In Advanced RET Fusion-Positive Lung Cancer

Eli Lilly And Co (NYSE:LLY) announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo (selpercatinib) in patients with RET fusion-positive non-small cell lung cancer (NSCLC). The updated analysis utilized a June 15, 2021, data cut-off. Among 247 patients previously treated with platinum chemotherapy, the confirmed objective response rate (ORR) was 61.1% and 84.1%…

Benzinga

If You Invested $100 In Eli Lilly 10 Years Ago, Here's How Much You Would Have Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.2% on an annualized basis producing an average annual return of 21.76%. Currently, Eli Lilly has a market capitalization of $274.87 billion.

Benzinga

FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting

The

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With LLY

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease

Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).

Benzinga

Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia

Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines."

Benzinga

Here's How Much $100 Invested In Eli Lilly 5 Years Ago Would Be Worth Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 13.68% on an annualized basis.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

According to a British study, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients…

StockNews.com

2 Top Pharmaceutical Stocks Down More Than 5% Year-to-Date to Buy Now

Despite logistical hindrances, the pharmaceutical industry has registered substantial growth over the past month, thanks to impressive innovation in the medical field and rapid technology integration. So, we think it could be wise to scoop up fundamentally sound pharmaceutical stocks Eli Lilly (LLY) and Novo Nordisk (NVO) on the dip…

Benzinga

FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population

The FDA approved Eli Lilly And Co (NYSE:LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure…

Benzinga

The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Eli Lilly Bets On RNA Potential With $700M Investment In Boston's Seaport

Eli Lilly And Co (NYSE: LLY)

Benzinga

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

Patients with moderately-to-severely active ulcerative colitis (UC) who took Eli Lilly And Co's (NYSE: LLY) mirikizumab

Benzinga

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals.

1 … 11 12 13 14

People

Dipanjan BanchurSince

722 stories

Peter Horby

17 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.